Home/ Stocks/ QURE

uniQure N.V.

QURE XNAS

$27.66 +3.62 (+14.99%) ▲ 15-min delayed

Open

$24.30

High

$29.49

Low

$23.49

Volume

6.72M

Market Cap

$1.74B

About uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 221 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$3.56M	$-53,535,000	$-0.85
FY 2025	$16.10M	$-198,971,000	$-3.46
Q3 2025	$3.70M	$-80,529,000	$-1.38
Q2 2025	$5.26M	$-37,719,000	$-0.69

Related Market News

No specific coverage for QURE yet. Check out our latest market news or earnings calendar.

Get QURE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on uniQure N.V..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.